SCHEMBL12777937

SCHEMBL12777937

CC(C)n1ccc(C(=O)N(C)C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.40
MALT1 Q9UDY8 1/20 0.36
KDM5A P29375 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
OGA O60502 2/20 0.32
NLRP3 Q96P20 1/20 0.32
SCN4A P35499 1/20 0.32
KDM4A O75164 1/20 0.32
HPGD P15428 2/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
MGLL Q99685 1/20 0.31
KMT2A Q03164 2/20 0.31
RAF1 P04049 1/20 0.31
MEN1 O00255 1/20 0.31
NQO2 P16083 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25859568 0.80 NPC1 (0.42) KDM5AHPGDALDH1A1SMN1; SMN2KMT2A
SCHEMBL10026473 0.79 MME (0.39) DYRK1AKDM5ANLRP3HPGDALDH1A1
SCHEMBL17065274 0.79 KDM5A (0.37) DYRK1AKDM5ANLRP3HPGDALDH1A1
SCHEMBL25332845 0.78 MEN1 (0.41) DYRK1AKDM5ANLRP3HPGDALDH1A1
SCHEMBL2810761 0.78 ADORA2A (0.40) DYRK1AKDM5ANLRP3HPGDADORA2A
SCHEMBL25616922 0.78 DPP4 (0.36) DYRK1AKDM5AOPRM1OPRL1ALDH1A1
SCHEMBL4425064 0.76 OPRM1 (0.52) MALT1OPRM1OPRL1HPGDALDH1A1
SCHEMBL19539129 0.75 BRD4 (0.42) MALT1KDM5AHPGDSMN1; SMN2MGLL
SCHEMBL1431340 0.75 KMT2A (0.44) KDM5AKMT2ARAF1MEN1
SCHEMBL28111818 0.75 KDM5A (0.35) DYRK1AKDM5ANLRP3HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902204-B2 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; HIV and AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-08 US disclosed
US-7902204-B2 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; HIV and AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-08 US disclosed
US-20080125439-A1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-05-29 US disclosed
US-20080125439-A1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125439-A1 DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS ZC3HAV1, ZC3HAV1L, EIF2AK2 DYRK1A 3636/4885MALT1 2379/4885KDM5A 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.